QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)

Prothena Stock Price, News & Analysis (NASDAQ:PRTA)

$33.00
+0.52 (+1.60%)
(As of 11/29/2023 ET)
Compare
Today's Range
$32.65
$33.89
50-Day Range
$32.31
$52.32
52-Week Range
$28.51
$79.65
Volume
461,543 shs
Average Volume
506,983 shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$91.00

Prothena MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
175.8% Upside
$91.00 Price Target
Short Interest
Bearish
11.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Prothena in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2.01 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.76) to ($4.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

443rd out of 949 stocks

Pharmaceutical Preparations Industry

198th out of 432 stocks


PRTA stock logo

About Prothena Stock (NASDAQ:PRTA)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

PRTA Stock Price History

PRTA Stock News Headlines

PRTA Dec 2023 105.000 call
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Cantor Fitzgerald Keeps Their Buy Rating on Prothena (PRTA)
Piper Sandler Keeps Their Buy Rating on Prothena (PRTA)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Earnings Preview For Prothena Corp
5 Biotech Stocks Set to Outpace Q3 Earnings Estimates
Prothena Corp. exploring a potential sale - Bloomberg
Prothena shares buoyed by sale rumors
Piper Sandler Remains a Buy on Prothena (PRTA)
See More Headlines
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRTA
Employees
127
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$91.00
High Stock Price Target
$129.00
Low Stock Price Target
$72.00
Potential Upside/Downside
+174.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-116,950,000.00
Pretax Margin
-61.37%

Debt

Sales & Book Value

Annual Sales
$53.90 million
Book Value
$11.50 per share

Miscellaneous

Free Float
38,531,000
Market Cap
$1.78 billion
Optionable
Optionable
Beta
0.45
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report














PRTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Prothena stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRTA shares.
View PRTA analyst ratings
or view top-rated stocks.

What is Prothena's stock price target for 2024?

7 equities research analysts have issued 1 year price objectives for Prothena's shares. Their PRTA share price targets range from $72.00 to $129.00. On average, they predict the company's share price to reach $91.00 in the next twelve months. This suggests a possible upside of 175.8% from the stock's current price.
View analysts price targets for PRTA
or view top-rated stocks among Wall Street analysts.

How have PRTA shares performed in 2023?

Prothena's stock was trading at $60.25 on January 1st, 2023. Since then, PRTA stock has decreased by 45.2% and is now trading at $33.00.
View the best growth stocks for 2023 here
.

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our PRTA earnings forecast
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) announced its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.64. The biotechnology company earned $84.87 million during the quarter, compared to analysts' expectations of $51.85 million. Prothena had a negative net margin of 51.92% and a negative trailing twelve-month return on equity of 12.06%.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

Who are Prothena's major shareholders?

Prothena's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.96%), Rock Springs Capital Management LP (1.14%), Bank of New York Mellon Corp (0.93%), Northern Trust Corp (0.76%), JPMorgan Chase & Co. (0.75%) and Avidity Partners Management LP (0.71%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago.
View institutional ownership trends
.

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PRTA) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -